The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma Meeting Abstract

  

Authors:	Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y.; Greil, R.; Mykhalska, L.; Burgués, J. M. B.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Costa, P. A.; Gau, J. P.; Hirata, J.; Jiang, Y.; Yan, M.; Lee, C.; Flowers, C. R.; Salles, G.
Abstract Title:	The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma
Meeting Title:	63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 2
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-12-04
Language:	English
ACCESSION:	WOS:000737693100002
DOI:	10.1182/blood-2021-154729
PROVIDER:	wos
Notes:	Meeting Abstract: LBA-1 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/192599